Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Antineoplastons: Phase II data

    Burzynski Research Institute Inc. (OTCBB:BZYR), Houston, Texas Product: Antineoplastons (ANP) therapy Business: Cancer Molecular target: NA Description: Combination of the synthetic amino acid derivatives Atengenal (…

    Published on 4/13/2015
  • Bavituximab: Additional Phase I data

    Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Tustin, Calif. Product: Bavituximab (3G4) Business: Cancer Molecular target: Phosphatidylserine Description: Chimeric mAb against phosphatidylserine Indication: Treat HER2-…

    Published on 4/13/2015
  • BL-8040: Phase I data

    Biokine Therapeutics Ltd., Tel Aviv, Israel BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Jerusalem, Israel Product: BL-8040 (formerly BKT-140) Business: Hematology Molecular target: CXC chemokine receptor 4 (CXCR4) (…

    Published on 4/13/2015
  • Bupivacaine collagen sponge: Clinical trial data

    Innocoll AG (NASDAQ:INNL), Athlone, Ireland Product: Bupivacaine collagen sponge, CollaRx bupivacaine Implant (XaraColl) Business: Neurology Molecular target: Sodium channel Description: Biodegradable and fully …

    Published on 4/13/2015
  • Dexamethasone-loaded punctum plug: Phase III data

    Ocular Therapeutix Inc. (NASDAQ:OCUL), Bedford, Mass. Product: Dexamethasone-loaded punctum plug (OTX-DP) Business: Neurology Molecular target: NA Description: Hydrogel-based punctum plug that delivers sustained- and …

    Published on 4/13/2015
  • DRM01: Phase IIa data

    Dermira Inc. (NASDAQ:DERM), Menlo Park, Calif. Product: DRM01 (formerly VAL-001, QLT91382) Business: Dermatology Molecular target: Acetyl-Coenzyme A carboxylase (ACAC) (ACC) Description: Topical prodrug of an acetyl-…

    Published on 4/13/2015
  • Exviera dasabuvir: Phase IIIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Exviera dasabuvir (ABT-333) Business: Infectious Molecular target: HCV NS5B polymerase Description: Non-nucleoside HCV NS5B polymerase inhibitor Indication: Treat chronic …

    Published on 4/13/2015
  • Exviera dasabuvir: Phase IIIb data

    AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Exviera dasabuvir (ABT-333) Business: Infectious Molecular target: HCV NS5B polymerase Description: Non-nucleoside HCV NS5B polymerase inhibitor Indication: Treat chronic …

    Published on 4/13/2015
  • Harmony Prenatal Test: Clinical trial data

    Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Harmony Prenatal Test Business: Diagnostic Molecular target: NA Description: Non-invasive prenatal multiplex assay that detects fetal trisomies 13, 18 and 21 in …

    Published on 4/13/2015
  • IBI-10090: Phase III data

    Icon Bioscience Inc., Sunnyvale, Calif. Product: IBI-10090 Business: Ophthalmic Molecular target: NA Description: Sustained-release formulation of dexamethasone delivered using Verisome technology Indication: Reduce …

    Published on 4/13/2015
  • Loteprednol etabonate mucosal penetrating particle: Phase II data

    Kala Pharmaceuticals Inc., Waltham, Mass. Product: Loteprednol etabonate mucosal penetrating particle, LE-MPP (KPI-121) Business: Ophthalmic Molecular target: NA Description: Loteprednol etabonate, a steroid, delivered …

    Published on 4/13/2015
  • Loteprednol etabonate mucosal penetrating particle: Phase III data

    Kala Pharmaceuticals Inc., Waltham, Mass. Product: Loteprednol etabonate mucosal penetrating particle, LE-MPP (KPI-121) Business: Ophthalmic Molecular target: NA Description: Loteprednol etabonate, a steroid, delivered …

    Published on 4/13/2015
  • Paliperidone palmitate: Phase III final data

    Alkermes plc (NASDAQ:ALKS), Dublin, Ireland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Paliperidone palmitate (3-month Invega Sustenna) Business: Neurology Molecular target: Monoamine receptors …

    Published on 4/13/2015
  • PXS4728A: Interim Phase I data

    Pharmaxis Ltd. (ASX:PXS; Pink:PXSLY), Frenchs Forest, Australia Product: PXS4728A Business: Inflammation Molecular target: Vascular adhesion protein-1 (VAP-1) (SSAO) Description: Oral vascular adhesion protein-1 (VAP-1;…

    Published on 4/13/2015
  • SHP625: Phase II data

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: SHP625 (formerly LUM001) Business: Hepatic Molecular target: Solute carrier family 10 sodium-dependent bile acid …

    Published on 4/13/2015
  • TILs: Phase I data

    Lion Biotechnologies Inc. (NASDAQ:LBIO), Woodland Hills, Calif. Product: TILs (LN-144) (formerly Contego) Business: Cancer Molecular target: NA Description: Autologous T cell therapy that utilizes tumor infiltrating …

    Published on 4/13/2015
  • Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Viekirax ombitasvir/paritaprevir/ritonavir Business: Infectious Molecular target: HCV NS3/4A protease complex; …

    Published on 4/13/2015
  • Viekirax ombitasvir/paritaprevir/ritonavir: Phase IIIb data

    Enanta Pharmaceuticals Inc. (NASDAQ:ENTA), Watertown, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Viekirax ombitasvir/paritaprevir/ritonavir Business: Infectious Molecular target: HCV NS3/4A protease complex; …

    Published on 4/13/2015
  • Xeljanz tofacitinib: Additional Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Xeljanz tofacitinib (Jaquinus) (CP-690,550) (formerly tasocitinib) Business: Autoimmune Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1) Description: Oral …

    Published on 4/13/2015
  • Xtandi enzalutamide: Phase II data

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Xtandi enzalutamide (formerly MDV3100) Business: Cancer Molecular target: Androgen receptor Description: Oral…

    Published on 4/13/2015
  • Adapalene 0: Phase III data

    Galderma S.A., Lausanne, Switzerland Product: Adapalene 0.3%/benzoyl peroxide 2.5% (0.3% A/BPO) Business: Dermatology Molecular target: NA Description: Topical gel formulation of adapalene 0.3% and benzoyl peroxide 2.5%…

    Published on 4/6/2015
  • AMR-001: Additional Phase II data

    NeoStem Inc. (NASDAQ:NBS), New York, N.Y. Product: AMR-001, NBS10 (formerly NBS-10) Business: Cardiovascular Molecular target: CD34; CXC chemokine receptor 4 (CXCR4) (NPY3R) Description: Autologous bone marrow-derived …

    Published on 4/6/2015
  • Asonep sphingomab: Additional Phase IIa data

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Product: Asonep sphingomab Business: Cancer Molecular target: Sphingosine 1-phosphate (S1P) receptor Description: Systemic formulation of a humanized mAb against sphingosine 1…

    Published on 4/6/2015
  • Avastin bevacizumab: Preliminary Phase III data

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Avastin bevacizumab (RG435) Business: Cancer Molecular …

    Published on 4/6/2015
  • Boniva ibandronate: Phase III data

    Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Taisho Pharmaceutical Holdings Co. Ltd. (Tokyo:4581), Tokyo, Japan GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Roche (SIX:ROG; OTCQX:RHHBY), Basel, …

    Published on 4/6/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993